Anders Rylander will remain in his role to ensure continuity and an orderly handover. The transition is expected to be completed during 2026 and, at the latest, by 31 December 2026. The Board has initiated the process of recruiting a new Chief Executive Officer.

“Biovica is entering a new phase of commercial growth. After 15 years as CEO, I believe this is a natural time to hand over to a new CEO who can accelerate US commercialization and expand clinical adoption,” says Anders Rylander. “I would like to thank the clinicians, research and commercial partners, employees and shareholders who have contributed to improving patient outcomes during my time as CEO. I intend to remain a long-term supporting shareholder of the company and, subject to shareholder approval, continue to contribute as a Board member.”

Chair of the Board Fredrik Alpsten comments:
“We would like to extend our sincere thanks to Anders Rylander for his dedication and contributions during his tenure as CEO. Under Anders’ leadership, Biovica successfully transformed from a research-driven company into a commercial-stage oncology diagnostics company. During this period the company achieved regulatory approvals in both the EU and the US for DiviTum^® TKa, established its US laboratory operations, initiated commercial sales and expanded its offering through Pharma Services. The Board looks forward to building on this foundation in the company’s next growth phase and confirms that the company’s strategy remains unchanged. We look forward to completing a structured transition together with Anders and, thereafter, wish him every success in his future professional endeavors.”

Further information regarding the recruitment process will be communicated in due course.